Eledon Pharmaceuticals, Inc.
@Eledon_Pharma
Followers
207
Following
0
Statuses
272
Targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune and neurodegenerative diseases. $ELDN
Irvine, California
Joined December 2020
We are grateful for this collaboration with our partner @eGenesisBio to advance new strategies in #transplantation and #immunosuppression to address the global shortage of available organs. $ELDN
Excited to announce our second patient was successfully transplanted with our genetically engineered porcine kidney. A historic milestone for #organ #transplantation. Thank you @mgh_transplant for being an incredible partner. Read the press release:
0
0
2
We are proud to have supported another landmark procedure with our novel investigational #immunosuppression therapy. Thank you to the team at @MassGeneralNews for the opportunity to contribute to this important advancement in #xenotransplantation. @mgh_transplant $ELDN
Mass General set another milestone. Jan 25th marked our 2nd successful xenotransplant of a genetically-edited pig kidney into a living recipient. Tim Andrews is now the 4th person in the world to receive a genetically-edited pig kidney.
0
3
4
Today we announced that our investigational therapy was used as a key component of the #immunosuppression regimen for the second patient to receive a transplanted kidney from a genetically modified pig in a procedure conducted by @MassGeneralNews: $ELDN
0
1
7
Since 1950, @nkf has played a crucial role in helping to improve kidney care and bring support to people affected by #KidneyDisease including #transplant recipients. Learn more about the key milestones that NKF has achieved over the past 75 years: $ELDN
0
1
3
Through our Phase 2 BESTOW clinical trial, we are focused on advancing a new solution in #immunosuppression therapy that may help prevent rejection in #KidneyTransplantation by supporting #transplant function and longevity. Learn more: $ELDN
0
1
4
$ELDN CEO @dalexgros and CSO Steven Perrin, Ph.D., will be participating in a fireside chat to share updates on our work to advance innovation in immunosuppression therapy for transplant recipients at the Guggenheim SMID Cap Biotech Conference. Learn more:
0
1
5
Years after being diagnosed with immunoglobulin A nephropathy, Amanda faced the difficult reality of needing a #KidneyTransplant. Her story shines a light on the power of family, self-advocacy, and the extraordinary impact of #LivingDonors: $ELDN
0
2
4
We believe that targeting the CD40L pathway could support the development of a new approach to #immunosuppression that may help increase #OrganTransplant function and longevity for #transplant recipients. Read more about our science here: $ELDN
0
1
4
With more than 100,000 people on the national organ transplant waitlist, #LivingDonors play a vital role in making lifesaving #OrganDonations possible. Learn more about the different types of living donor #transplants from @KidneyFund here: $ELDN
0
0
1
The average #KidneyTransplant recipient experiences kidney failure within 10-15 years post-transplant, often leading to a recurring cycle that involves transitioning between dialysis and #transplantation multiple times throughout their lifetime: $ELDN
0
0
2
We are deeply inspired by the selfless generosity of #OrganDonors like Peyton Nurse, who was posthumously honored during the New Year’s Day Rose Parade in Pasadena, CA, for saving three lives through #OrganDonation. Read more: @nbcsandiego $ELDN
0
0
2
From completing enrollment in our Phase 2 BESTOW study to supporting the #immunosuppression treatment regimens used in groundbreaking islet and xenograft #transplant research, 2024 marked a year of significant progress for Eledon. Learn more: $ELDN
0
1
2
As 2024 comes to a close, we would like to thank the patients and families throughout the transplant community, clinicians, and $ELDN team members who helped make this a transformative year by supporting the advancement of new solutions in #immunosuppression and #transplantation.
0
1
4
This year, $ELDN CEO @dalexgros sat down with basketball legend @seanelliott_32 for a special discussion commemorating the 25th anniversary of his #KidneyTransplant. Watch the interview to hear perspectives on key issues related to #KidneyTransplantation:
0
1
4
In his search for solutions to help overcome challenges associated with acute onset type 1 #diabetes, Daniel set out on a journey that eventually led to his participation in an investigator-initiated islet #transplant clinical trial. Read more: $ELDN
0
1
4
Our research focuses on the potential to target the CD40L pathway to develop a new approach to #immunosuppression that may help protect transplanted organs and prevent #transplant rejection. Learn more about our science here: $ELDN
0
1
4
$ELDN CEO @dalexgros shares insights on the @UChicagoMed study assessing an immunosuppression regimen including our investigational therapy, tegoprubart, to prevent islet transplant rejection in subjects with type 1 diabetes in this @OCBizJournal article:
0
2
7
In the latest issue of Drug Development & Delivery, $ELDN CEO @dalexgros provides a comprehensive overview of several key advances in our research targeting the CD40L pathway to help prevent rejection in organ and islet #transplantation. Read more:
0
5
6
In our work to advance #immunosuppression research to improve support for #transplant recipients, we are inspired by the generosity of #LivingDonors like Sandy Flash, who donated part of her liver to help save a 1-year-old with biliary atresia: @ABC $ELDN
0
2
3
In our Phase 2 BESTOW clinical trial, we are assessing the potential to target the CD40L pathway to help increase the function and longevity of #KidneyTransplants. Learn more about our ongoing research in #immunosuppression here: $ELDN
0
1
2